The hearing will address the complexities involved with conducting research on cannabidiol, a Schedule I substance, as well as its potential medical benefits and risks in treating serious illnesses such as intractable epilepsy.
The hearing will address the complexities involved with conducting research on cannabidiol, a Schedule I substance, as well as its potential medical benefits and risks in treating serious illnesses such as intractable epilepsy.
Deputy Assistant Administrator of Drug Diversion with the Drug Enforcement Administration (DEA), Washington, D.C.
Deputy Director for the Center for Drug Evaluation and Research, Food and Drug Administration, Washington, D.C.
Director, National Institute on Drug Abuse, Washington, D.C.